G Protein Coupled Receptors (GPCR) Market – Trends Forecast Till 2031

Market Snapshot

Market Overview

The global G protein Coupled Receptors (GPCR) Market size was estimated at USD 3,340 million in 2024 and is projected to reach USD 5,258.9 million in 2031 at a CAGR of 6.7 % during the forecast period 2025-2031.

The G Protein-Coupled Receptors (GPCR) market involves the development and commercialization of therapeutic drugs targeting these receptors, which play a critical role in various physiological processes. GPCRs are involved in numerous biological functions such as neurotransmission, immune response, and sensory perception, making them key targets for drug discovery and development. The market for GPCR-targeted drugs is driven by the need to treat a wide array of diseases, including cardiovascular disorders, cancer, neurological diseases, and metabolic conditions, as these receptors are implicated in the mechanisms of many health conditions.

The scope of the GPCR market covers a broad spectrum of pharmaceutical and biotechnology companies engaged in drug discovery, development, and commercialization. With an estimated 800 different types of GPCRs in the human body, the potential for novel therapeutics targeting these receptors is vast. The market includes both small molecule drugs and biologics, as well as research into new drug delivery systems. Additionally, there is significant interest in developing GPCR-based diagnostics and personalized medicine solutions to better address the diverse needs of patients.

Key trends in the GPCR market include the increasing use of artificial intelligence (AI) and machine learning in drug discovery, which allows for more efficient identification of potential GPCR targets. Another important trend is the growing focus on biased signaling pathways, where different drugs targeting the same receptor may have distinct therapeutic effects depending on how they modulate receptor activity. Advances in the understanding of GPCR structures, such as the development of high-resolution imaging techniques, are also enabling the creation of more targeted and effective drugs. Additionally, the rise of precision medicine is influencing the development of treatments tailored to individual patient profiles based on specific GPCR pathways.

The main drivers of the GPCR market include the increasing prevalence of chronic diseases such as cardiovascular and neurological disorders, which heighten the demand for novel therapeutics. Research and development in biotechnology and pharmaceutical companies are focusing on unlocking the full therapeutic potential of GPCRs, fueled by their critical roles in human biology. The development of more advanced drug discovery tools, growing investment in biotech startups, and the expansion of research into orphan diseases further drive the market. Moreover, regulatory support for biologics and personalized medicine is accelerating the development of GPCR-targeted treatments, which are expected to offer better outcomes and fewer side effects than traditional therapies.

Delvens Industry Expert's Standpoint

Experts in the G protein Coupled Receptors (GPCR) Market highlight several key trends driving growth and innovation. The G Protein-Coupled Receptors (GPCR) market focuses on developing therapeutics targeting GPCRs, which are critical in various biological functions and are implicated in many diseases. The market spans pharmaceutical and biotech companies working on small molecule drugs, biologics, and diagnostics. Key trends include the use of AI in drug discovery, exploration of biased signaling pathways, and advancements in GPCR structure research, enabling more precise treatments. The market is driven by the rising prevalence of chronic diseases, increased R&D in biotechnology, and growing interest in personalized medicine. These factors, along with regulatory support, are fueling the development of innovative GPCR-targeted therapies.

Market Portfolio

Key Findings

• The G-protein coupled receptors industry is divided into cell lines and detection kits. The cell lines segment holds a prominent position in the market, driven by the availability of a broad range of cell lines used in various assays. These cell lines are vital for conducting cellular impedance assays that detect GPCR targets, making them essential in the research and development of new therapeutic solutions. Meanwhile, detection kits have gained increasing popularity due to their ease of use, robustness, and high sensitivity, allowing for accurate evaluation of GPCR activity through multiple pathways. The introduction of nonlabelled detection systems is further supporting the growth of this segment.

• The G-protein coupled receptors industry also segments its assays into categories like cAMP functional assays, calcium functional assays, and several other specialized tests. The cAMP functional assays segment is crucial due to the importance of cyclic Adenosine Monophosphate (cAMP) in GPCR signal transduction. The availability of a variety of reagent kits for measuring cAMP levels supports the widespread use of these assays in GPCR research. As the understanding of GPCRs advances, cAMP assays remain a core method for investigating receptor activity and cellular responses.

• The calcium functional assays segment is expected to grow due to the increasing demand for assays that measure calcium flux. Calcium flux assays are highly valued for their sensitivity and ease of use, making them an attractive option for researchers. The flexibility of these assays in terms of user configurability also contributes to their rising popularity, particularly in the study of GPCR-mediated signaling pathways. As new applications emerge, the role of calcium functional assays in GPCR research continues to expand.

• The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America region is projected to hold the largest market share. Factors such as increasing prevalence of chronic diseases, advancements in drug discovery, rising demand for personalized medicine, increasing R&D investments, growing pharmaceutical industry, expanding biotechnology sector, and advancements in GPCR-targeted therapies have triggered the G protein Coupled Receptors (GPCR) Market in the region.

Regional Analysis

North America to Dominate the Market

• In North America, the GPCR market remains dominant, supported by a strong pharmaceutical industry, extensive R&D capabilities, and advanced healthcare infrastructure. The presence of leading biotech and pharmaceutical companies, along with a focus on innovation and the development of novel therapies targeting GPCRs, ensures sustained market growth. Furthermore, the region’s robust investment in biotechnology, combined with high healthcare expenditure, provides a conducive environment for the development of GPCR-targeted drugs, making it a hub for drug discovery and clinical trials.

• In Europe, the GPCR market is steadily expanding, driven by increasing investments in healthcare and pharmaceutical R&D. The region has seen significant collaborations between academic institutions, research organizations, and pharmaceutical companies, contributing to the advancement of GPCR-targeting drug discovery. Additionally, the rising prevalence of chronic diseases and aging populations in countries like Germany, the UK, and France is fueling the demand for GPCR-based therapeutics. However, the regulatory environment and economic challenges in some European countries might slow the pace of market growth in certain areas.

• The Asia-Pacific region is witnessing the most rapid growth in the GPCR market. This growth is driven by significant investments in healthcare and an increasing demand for improved medical treatments, especially in emerging markets like China, India, and Japan. The expansion of pharmaceutical research, the growing middle-class population, and the rising incidence of chronic diseases are contributing to the rising demand for GPCR-targeted drugs. Moreover, as countries in the region increasingly focus on advancing their healthcare infrastructures and biotechnology sectors, the Asia-Pacific market is expected to become a major player in the GPCR landscape in the coming years.

• In the Middle East and Africa, the GPCR market is still in the early stages of development but shows great potential. Countries in the Gulf Cooperation Council (GCC) like Saudi Arabia, the UAE, and Qatar are seeing increased investments in healthcare infrastructure, creating opportunities for growth in the pharmaceutical sector. However, the market in Africa remains relatively underdeveloped, primarily due to limited healthcare access, regulatory challenges, and economic disparities. Despite this, growing healthcare needs and increasing interest in advanced therapeutics could drive future demand for GPCR-based drugs in both the Middle East and African regions.

Competitive Landscape

• Thermo Fisher Scientific Inc.
• Eurofins Scientific
• QIAGEN
• WuXi AppTec
• Promega Corporation
• Abcam plc
• Merck KGaA
• PerkinElmer Inc.
• Enzo Biochem Inc.
• BD

Recent Developments

• In January 2025, Isogenica and Cube Biotech announced a strategic collaboration to accelerate the development of GPCR-targeted therapeutics. This partnership combines Cube Biotech’s advanced GPCR stabilization technology with Isogenica’s proprietary synthetic VHH libraries, aiming to streamline the discovery of antibodies for challenging GPCR targets.

• In September 2024, Superluminal Medicines, Inc., a biotechnology company based in Boston, successfully closed a USD 120 million Series A funding round. The round was led by RA Capital Management, with participation from Insight Partners, NVentures (the venture capital arm of NVIDIA), Catalio Capital Management, Eli Lilly and Company, Gaingels, and Cooley LLP.

• In August 2022, Sosei Group Corporation and AbbVie Inc., a global research-based biopharmaceutical company, entered into a new drug discovery partnership and option-to-license agreement. The primary goal of this collaboration is to identify, develop, and bring to market small molecules that target novel G protein-coupled receptors (GPCRs) linked to neurological diseases.

• In April 2021, Tectonic Therapeutics launched with a successful Series A financing round, raising USD 80 million. The company aims to revolutionize the discovery of novel therapies targeting G-Protein Coupled Receptors (GPCRs).

Reasons to Acquire

• Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.
• Gain authentic and granular data access for the G protein Coupled Receptors (GPCR) Market to understand the trends and the factors involved in changing market situations.
• Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.
• In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.

Report Scope